Fig. 4

PCSK9 inhibition enhanced MHC-II expression and CD8⁺ T cell activation in vitro (A) Flow cytometry staining of the ratios of DCs (MHC-II⁺CD11c⁺) and CD103⁺ DCs in spleen cells after direct treatment of different concentrations (0, 2, and 10 µM) of PCSK9i for 48 h. (B-C) MFC tumor cells were pretreated with PCSK9i (0 and 10 µM) for 24 h and then cocultured with spleen cells for another 12 h. The activation marker expression on CD4⁺ T cells and CD8⁺ T cells was detected by flow cytometry. (D) Flow cytometry detection of the lysis of monolayer PB-labeled MFC tumor cells pretreated by different concentrations (0, 2, and 10 µM) of PCSK9i for 24 h and then co-cultured with T cells at an E: T ratio of 10:1. Data with error bars are shown as mean ± SEM